Trexall 10 Original price was: Tk. 150.Current price is: Tk. 134.
Back to products
Evania 25 Original price was: Tk. 270.Current price is: Tk. 248.

Adalimab 40

Injection - 40mg/0.8ml
Generic: Adalimumab
1 Injection

Original price was: Tk. 15,000.Current price is: Tk. 13,350.

Description

Introduction
Adalimab 40 is a medicine used to treat a variety of conditions such as ankylosing spondylitis, rheumatoid arthritis, psoriasis, ulcerative colitis, and Crohn’s disease. It provides relief from swelling, pain, and redness associated with various disorders and improves physical function. Adalimab 40 is given by a healthcare professional and should not be self-administered. You should use it regularly and at the same time each day to get the maximum benefit from it. Continue using it as recommended by your doctor and complete the dose even if you feel better. Some of the common side effects of this medicine include headache, sinus inflammation, rash upper respiratory tract infection, and injection site reactions such as pain, redness, and swelling. Talk to your doctor if any of these side effects do not go away with time or get worse. Your doctor may help with ways to reduce or prevent these symptoms. To make sure the medicine is safe for you, before taking it, let your doctor know if you have any problems with your heart, kidneys, or liver. You should also tell your doctor about all the other medicines you are taking. It is important for pregnant and breastfeeding women to ask the advice of their doctors before taking this medicine.

_
Uses of Adalimab 40
Ankylosing spondylitis
Rheumatoid arthritis
Psoriasis
Ulcerative Colitis
Crohn’s disease
Side effects of Adalimab 40
Common
Headache
Sinus inflammation
Rash
Upper respiratory tract infection
Injection site reaction
How to use Adalimab 40
Your doctor or nurse will give you this medicine. Kindly do not self administer.
How Adalimab 40 works
Adalimab 40 blocks the action of certain chemical messengers that are responsible for inflammation, swelling and redness associated with certain joint diseases.
What if you forget to take Adalimab 40?
If you miss a dose of Adalimab 40, please consult your doctor.
Quick Tips
It is given by injection under the skin (via subcutaneous).
Take it as per the dose and duration suggested by the doctor.
Inform your doctor immediately if you notice severe rash, hives, swelling of hands or face and shortness of breath.
Store the pen in the refrigerator. When refrigeration is not possible, you can also keep your pen at room temperature (less than 30°C) for up to 2 weeks. Do not freeze it.
Do not stop taking the medication suddenly without talking to your doctor first.
Brief Description
Indication
Rheumatoid arthritis, Ankylosing spondylitis; Psoriatic arthritis, Crohn’s disease; Ulcerative colitis, Plaque psoriasis, Juvenile Rheumatoid Arthritis
Administration
Instruct patients using the pen or prefilled syringe to inject the full amount in the syringe, according to the directions provided Injections should occur at separate sites in the thigh or abdomen; rotate injection sites and do not give injections into areas where the skin is tender, bruised, red, or hard

_
Adult Dose
Subcutaneous Rheumatoid arthritis, Ankylosing spondylitis, Psoriatic arthritis Adult: 40 mg as a single dose every other wk. May increase to wkly dosing when used as monotherapy. Crohn’s disease, Ulcerative colitis Adult: Moderate to severe active disease: Initially, 160 mg (given as four 40-mg inj in 1 day or as two 40-mg inj for 2 consecutive days), then 80 mg 2 wk after the initial dose (day 15). Maintenance: After 2 wk (day 29), 40 mg every other wk, may increase to 40 mg wkly if needed. Review treatment if no response w/in 8 (ulcerative colitis) or 12 (Crohn’s disease) wk of therapy. Plaque psoriasis Adult: Initially, 80 mg. Maintenance: 40 mg every other wk beginning 1 wk after 1st dose.

_
Child Dose
Subcutaneous Juvenile idiopathic arthritis Child: >4 yr 15 to <30 kg: 20 mg every other wk; >30 kg: 40 mg every other wk.

_
Contraindication
None listed on FDA-approved label.
Mode of Action
Adalimumab is a recombinant DNA-derived human Ig G1 monoclonal antibody. It binds to human tumour necrosis factor alfa (TNF-alpha), thus interfering w/ cytokine-driven inflammatory processes.
Precaution
Patient w/ pre-existing or recent onset central or peripheral nervous system demyelinating disorders, heart failure or decreased left ventricular function; at risk of hepatitis B virus (HBV) infection. Reactivation and new onset of TB infection. Patient who travelled to or resided in regions where TB is endemic. Elderly. Pregnancy and lactation. Monitoring Parameters Perform tuberculin skin test and HBV screening prior to treatment. Monitor for signs and symptoms of infection prior to, during and following treatment. Lactation: Limited data from published literature indicate that adalimumab is present in low levels in human milk and is not likely to be absorbed by a breastfed infant

_
Side Effect
>10% Injection site pain (12-20%),Upper respiratory tract infection (URTI) (17%),Increased creatine phosphokinase (15%),Headache (12%),Rash (12%),Sinusitis (11%) 1-10% Nausea (9%),Urinary tract infection (UTI) (8%),Abdominal pain (7%),Flulike syndrome (7%),Hyperlipidemia (7%),Back pain (6%),Hypercholesterolemia (6%),Hematuria (5%),Hypertension (5%),Increased alkaline phosphatase (5%) <1% Allergic reactions,Hematologic disorder (leukopenia, thrombocytopenia, pancytopenia, aplastic anemia) Potentially Fatal: Sepsis, opportunistic infections, TB, HBV reactivation, other malignancies (e.g. leukaemia, lymphoma, hepatosplenic T-cell lymphoma), haematological, neurological and autoimmune reactions, anaphylaxis, angioneurotic oedema. _ Pregnancy Category Note Pregnancy Available studies with use of adalimumab during pregnancy do not reliably establish an association between adalimumab and major birth defects Clinical data are available from the Organization of Teratology Information Specialists (OTIS)/Mother-To-Baby HUMIRA Pregnancy Registry in pregnant women with rheumatoid arthritis (RA) or Crohn disease (CD) Registry results showed a rate of 10% for major birth defects with first trimester use of adalimumab in pregnant women with RA or CD and a rate of 7.5% for major birth defects in the disease matched comparison cohort The lack of pattern of major birth defects is reassuring and differences between exposure groups may have impacted the occurrence of birth defects Adalimumab is actively transferred across the placenta during the third trimester of pregnancy and may affect immune response in the in-utero exposed infant Clinical consideration Disease-associated maternal and embryo/fetal risk Published data suggest that the risk of adverse pregnancy outcomes in women with RA or inflammatory bowel disease (IBD) is associated with increased disease activity Adverse pregnancy outcomes include preterm delivery (ie, <37 weeks gestation), low birth weight (ie, <2500 g) infants, and small for gestational age at birth Fetal/neonatal adverse reaction Monoclonal antibodies are increasingly transported across the placenta as pregnancy progresses, with the largest amount transferred during the third trimester Risks and benefits should be considered prior to administering live or live-attenuated vaccines to infants exposed to adalimumab in utero owing to possible effect on infant immune system Lactation Limited data from case reports in published literature describe presence of adalimumab in human milk at infant doses of 0.1-1% of maternal serum level; there are no reports of adverse effects of adalimumab on breastfed infant and no effects on milk production; developmental and health benefits of breastfeeding should be considered along with mother’s clinical need for therapy and any potential adverse effects on breastfed child from drug or from underlying maternal condition _ Interaction Increased risk of serious infections w/ other biologic disease-modifying antirheumatic drugs (e.g. abatacept, anakinra), rituximab. May increase immunosuppressant effect w/ tocilizumab, live vaccines. ব্যবসার জন্য পাইকারি দামে পণ্য কিনতে রেজিস্টেশন করুন Register 3629 People recently viewed this Adalimab 40 Injection - (40mg/0.8ml) arogga-brand Healthcare Pharmaceuticals Ltd. Generic: Adalimumab Out of Stock Currently unavailable, please request or choose another variant. 1 Injection ৳ 14140.00 ৳ 15000 6% OFF Notify Additional Offers Cashback ৳50 For purchasing above ৳5000+ Cashback ৳40 For purchasing above ৳4000+ Cashback ৳30 For purchasing above ৳3000+ Cashback ৳20 For purchasing above ৳2000+ Cashback ৳10 For purchasing above ৳1000+ Alternative Brands For Adalimab 40 Sort by: Relevance Advixa 40mg/0.8ml injection Advixa 40 By In

0 reviews
0
0
0
0
0

There are no reviews yet.

Be the first to review “Adalimab 40”

Your email address will not be published. Required fields are marked *